Advancing Non-Viral, Non-Lipid Genetic Medicines
Genexys BioMed is pioneering safe, re-dosable gene therapies. Learn more about our innovative GeneZip platform.
About Us
A subsidiary of Orange Grove Bio, Genexys BioMed is at the forefront of next-generation genetic medicines, transforming treatment for cystic fibrosis (CF) and other genetic diseases. Powered by cutting-edge research from Cincinnati Children’s Hosptial Medical Center, we are developing a non-viral, non-lipid nanoparticle platform designed for safe, durable, and re-dosable gene therapies.
Our Science
Genexys BioMed is not just advancing gene therapy—we're redefining its future.
"We are excited to see the progress of Genexys BioMed in advancing our gene therapy approach and platform for CF. This collaboration between academia and industry exemplifies how research can be translated into therapies for patients. We look forward to Genexys BioMed bringing this promising technology closer to clinical application.”
Dr. Assem Ziady
Cincinnati Children’s Hospital
Investing in the Future of Gene Therapy
Genexys BioMed is advancing a safe and scalable gene therapy platform to address major gaps in genetic medicine and we are poised to transform treatment for CF and other monogenic diseases. Join us in revolutionizing genetic medicine.